Harvard Medical School, Massachusetts General Hospital, Department of Radiation Oncology, Boston, MA 02114, USA.
Curr Urol Rep. 2013 Apr;14(2):109-15. doi: 10.1007/s11934-012-0301-x.
During the past 25 years, prospective clinical trials have established that bladder preservation therapy for select patients with muscle-invasive bladder cancer is a safe and effective alternative to an immediate cystectomy. Cisplatin-based chemoradiation is the most well-studied and accepted component of trimodality therapy; however, other systemic agents have recently been shown effective in combination with radiation therapy, increasing the range of options to allow for better personalization of care. In this review, the most recent advances in the field of bladder-preserving trimodality therapy are presented, and future directions for improving the outcomes are outlined.
在过去的 25 年中，前瞻性临床试验已经证实，对于选择的肌层浸润性膀胱癌患者，膀胱保留疗法是一种安全有效的替代方法，可替代立即进行的膀胱切除术。顺铂为基础的放化疗是三联疗法中研究最多和最被接受的组成部分；然而，其他系统药物最近已被证明与放射治疗联合有效，从而增加了选择范围，使护理能够更好地个性化。在这篇综述中，介绍了膀胱保留性三联疗法领域的最新进展，并概述了改善治疗效果的未来方向。
